Study wrapper · #1321
Multi-Database Pharmacovigilance Analysis of Gastroesophageal Reflux Disease Associated with GLP-1 Receptor Agonists: A Cross-National Signal Validation Study.
Editor's note
The strength here is replication: the same directional signal appears in Western and Asian reporting systems, using an active comparator rather than the whole database, which blunts some of the usual disproportionality artefacts. The weakness is inherent to the method — spontaneous reporting captures what gets reported, not incidence, and the JADER counts (19 versus 16 cases) are far too small to carry the reported 4.76-fold estimate on their own. For readers tracking GLP-1 tolerability, reflux belongs on the list of gastrointestinal effects to watch alongside nausea and delayed gastric emptying, particularly at higher doses and in older users.
Plain-language abstract
Researchers combed through three national side-effect reporting databases (from the United States, Japan, and Canada) covering more than 260,000 reports involving GLP-1 receptor agonists, and compared them against an older diabetes drug class. Acid reflux was reported roughly two to five times more often with GLP-1 drugs, with the largest signal for semaglutide and a comparable one for tirzepatide. The signal grew stronger with age, and one older drug in the class, exenatide, went the other way. Because these are voluntary reports rather than a controlled trial, the numbers show a consistent pattern of reporting, not a measured rate of reflux in users.